Agenus Inc. (AGEN) Can’t Burn Your Long Portfolio. Has Another Strong Session

February 15, 2018 - By Dolores Ford

Investors sentiment increased to 1.34 in 2017 Q3. Its up 0.29, from 1.05 in 2017Q2. It increased, as 14 investors sold Agenus Inc. shares while 18 reduced holdings. 15 funds opened positions while 28 raised stakes. 36.96 million shares or 3.93% less from 38.48 million shares in 2017Q2 were reported.
Moreover, Manufacturers Life Insur Communication The has 0% invested in Agenus Inc. (NASDAQ:AGEN) for 61,860 shares. Meeder Asset Mgmt Inc has 454 shares for 0% of their portfolio. Price T Rowe Assoc Md reported 0% stake. California State Teachers Retirement Sys invested in 118,057 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 88,942 shares or 0% of its portfolio. Moreover, Crestwood Advisors Grp Ltd has 0.01% invested in Agenus Inc. (NASDAQ:AGEN) for 32,928 shares. Fmr Lc invested 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Morgan Stanley reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Oracle Invest has 1.60M shares. Walleye Trading Llc invested in 0% or 32,000 shares. Ingalls & Snyder Llc holds 15,100 shares or 0% of its portfolio. Rhumbline Advisers owns 86,868 shares or 0% of their US portfolio. 2 were accumulated by Pathstone Family Office Ltd Liability Com. Blair William Il invested 0% in Agenus Inc. (NASDAQ:AGEN). Bancorporation Of America De holds 0% or 7,101 shares in its portfolio.

Since October 9, 2017, it had 0 insider buys, and 5 insider sales for $95,988 activity. Another trade for 8,358 shares valued at $28,921 was made by Valentine Karen on Monday, October 9. Duncan Alex sold $22,651 worth of stock or 6,546 shares. $12,152 worth of Agenus Inc. (NASDAQ:AGEN) shares were sold by Buell Jennifer. KLASKIN CHRISTINE M sold 5,610 shares worth $19,418.

The stock of Agenus Inc. (NASDAQ:AGEN) is a huge mover today! The stock increased 9.92% or $0.381 during the last trading session, reaching $4.221. About 1.58 million shares traded or 39.27% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 2.26% since February 15, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.
The move comes after 8 months positive chart setup for the $430.39 million company. It was reported on Feb, 15 by We have $4.52 PT which if reached, will make NASDAQ:AGEN worth $30.13 million more.

Analysts await Agenus Inc. (NASDAQ:AGEN) to report earnings on March, 8. They expect $-0.37 EPS, down 23.33 % or $0.07 from last year’s $-0.3 per share. After $-0.37 actual EPS reported by Agenus Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Agenus Inc. (NASDAQ:AGEN) Ratings Coverage

Among 5 analysts covering Agenus (NASDAQ:AGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Agenus had 10 analyst reports since July 27, 2015 according to SRatingsIntel. H.C. Wainwright downgraded the stock to “Neutral” rating in Friday, October 28 report. The stock of Agenus Inc. (NASDAQ:AGEN) earned “Buy” rating by Jefferies on Wednesday, December 16. Maxim Group maintained the shares of AGEN in report on Thursday, October 27 with “Buy” rating. The stock has “Hold” rating by Maxim Group on Tuesday, October 27. The firm earned “Buy” rating on Friday, July 29 by Jefferies. The firm has “Buy” rating by Jefferies given on Thursday, August 3. The firm has “Buy” rating by Maxim Group given on Friday, March 11. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Buy” rating on Monday, July 27 by MLV. Jefferies maintained Agenus Inc. (NASDAQ:AGEN) on Monday, June 26 with “Buy” rating.

More recent Agenus Inc. (NASDAQ:AGEN) news were published by: which released: “The case for Agenus” on February 13, 2018. Also published the news titled: “Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884 …” on January 22, 2018.‘s news article titled: “Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty …” with publication date: January 22, 2018 was also an interesting one.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $430.39 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.